Key Highlights
- Biren Amin appointed as managing director and senior research analyst, focusing on biotechnology companies.
- Amin brings a wealth of experience from his previous roles, including CFO and CSO at Pyramid Biosciences, and a decade of biotech sector coverage at Jefferies Financial Group.
- Piper Sandler aims to bolster its biopharma equity research platform, benefiting from Amin’s insights into oncology, CNS disorders, ophthalmology, and rare diseases.
Source: Business Wire
Notable Quote
- “We are excited to welcome Biren to the equity research team. His well-respected and recognized biotechnology research experience, along with public and private company CFO experience, will expand and strengthen our industry-leading platform of biopharma equity research,” – Michael Cox, Co-Head of Global Equities at Piper Sandler
SoHC's Take
Piper Sandler’s addition of Biren Amin to its healthcare equity research team marks a strategic move to deepen its expertise and coverage within the biotechnology sector. Amin’s distinguished career, spanning roles from CFO to senior research analyst, equips him with a unique perspective on both the financial and scientific facets of biopharma. This appointment underscores Piper Sandler’s commitment to providing clients with actionable and insightful research, leveraging Amin’s extensive experience to navigate the complexities of biotechnology investments. As the industry continues to evolve, Amin’s role will be pivotal in identifying emerging opportunities and challenges within the biotech landscape, offering valuable insights to Piper Sandler’s clients.
